關于我們 About
發展歷程
當前位置: 首頁 > 關于我們 > 發展歷程

image.png


2020年,新建上海臨港研發中心及中試基地,中國醫藥工業百強(CRO/CDMO)20強

In 2020, Newly built Shanghai Lingang R & D center and pilot-scale base, top 20 of China's top 100 enterprises of pharmaceutical industry (CRO / CDMO)


2019年,上海、南京、成都三地新研發中心投入運營。

In 2019, Three research centers in Shanghai, Nanjing and Chengdu established and in operating.


2018年,業務能力提升,研發管線進一步豐富。

In 2018, Internal capabilities upgraded,and R&D pipeline enriched.


2017年,數據追蹤系統實現Waters網絡版覆蓋,年研發服務合同金額過億。

In 2017, the Waters data online tracking system was completed, and the annual R&D service contract amount exceeded 100 million.


2016年,收購臨床CRO--成都潤澤醫藥科技開發有限公司,開啟藥物全流程研發服務模式。

In 2016, the company acquired the clinical CRO--Chengdu Runze Pharmaceutical Technology Development Co., Ltd., and started the drug whole process R&D service model.


2014年,第一個臨床批件(奧拉西坦注射液)和第一個生產批件(樂卡地平原料藥)獲得批準。

In 2014, the first clinical approval (Olaracetam Injection) and the first production approval (Lecapine API) were obtained.


2012年,上海博志研新藥物技術有限公司成立,開展從事藥物發現,原料藥及中間體研發,高端制劑研發等一系列研發服務。

In 2012, Shanghai Bocimed Pharmaceutical Co., Ltd was established to carry out a series of research and development services such as drug discovery, APIs and intermediates and high-end preparations.

COPYRIGHT 2015 上海博志研新藥物技術有限公司 滬ICP備13030567號-1 本公司保留一切版權 | 條款及細 上海浦東新區松濤路647弄1號樓

滬公網安備 31011502005223號